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Size-dependent protein segregation at the cell–cell contact interface has been suggested to
be critical for regulation of lymphocyte function. We investigated the role of ligand
dimensions in regulation of mouse NK-cell activation and inhibition. Elongated forms of
H60a, a mouse NKG2D ligand, were generated and expressed stably in the RMA cell line.
RMA cells expressing the normal size H60a were lysed efﬁciently by both freshly isolated
and IL-2 stimulated C57BL/6 mouse-derived NK cells; however the level of lysis decreased
as the H60a ligand size increased. Importantly, H60a elongation did not affect NKG2D
binding, as determined by soluble NKG2D tetramer staining, and by examining NK-cell
target cell conjugate formation. CHO cells are efﬁcient at activating NK cells from C57BL/6
mice, and expression of a single chain form of H-2K
b, a ligand for the mouse inhibitory
receptor Ly49C, strongly inhibited such activation of Ly49C/I positive NK cells. Elongation
of H-2K
b resulted in decreased inhibition of both lysis and IFN-c production by NK cells.
These results establish that small ligand dimensions are important for both NK-cell
activation and inhibition, and suggest that there are shared features between the
mechanisms of receptor triggering on different types of lymphocytes.
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Introduction
Receptor–ligand interactions are of fundamental importance in
the regulation of lymphocyte function. Extensive information is
now available on structural features of lymphocyte receptors, and
the signalling pathways they initiate. However, the mechanisms
of lymphocyte receptor triggering, deﬁned as the sequence of
molecular events that link receptor ligation to initiation of the
signalling pathways, remain much less well characterized. It has
been proposed that the relatively small dimensions of receptor-
ligand pairs are critical for lymphocyte receptor triggering, as
they allow size-dependent protein segregation at the contact
interface between cells [1].
The importance of ligand dimensions for CD8
1 T-cell activa-
tion has been demonstrated by experimental elongation of MHC
class I molecules, which resulted in a marked reduction of TCR-
dependent signalling and T-cell effector function [2, 3]. A similar
dependence on ligand size has been demonstrated for T cells
expressing a chimeric TCR [4]. The signiﬁcance of size-dependent
segregation of proteins during lymphocyte interactions has also
been shown by elongation of CD48, a ligand for the T-cell
co-receptor CD2 [5, 6], and by experimental reduction in size of
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reduction in T-cell activation. A requirement for optimal ligand
dimensions in T-cell activation is therefore of importance when
manipulating TCR and their ligands for possible therapeutic
purposes. For example, T cells expressing a chimeric TCR that
recognises a membrane-distal epitope on CD22 have reduced
effector functions on CD22 positive target cells, as compared with
T cells expressing a TCR recognising a membrane-proximal
epitope [8]. Because CD22 is upregulated on B-cell lymphomas,
this higher level of expression allows the T cells with the TCR
recognising the membrane-distal epitope on CD22 to lyse
lymphoma cells, while sparing normal B cells [8].
We wanted to investigate whether ligand dimensions are also
important in NK-cell activating and inhibitory receptor triggering.
NK cells are the third largest lymphocyte population and play a
key role in the recognition and elimination of viruses and
tumours. Identiﬁcation of abnormal cells, using sets of activating
and inhibitory receptors, initiates NK-cell-mediated killing and
cytokine production. NK-cell activating receptors, such as NKG2D
and Ly49H, recognise stress-induced ligands or virus-derived
molecules, respectively. Inhibition of NK-cell function is mediated
by inhibitory receptors such as Ly49C and CD94/NKG2A that
interact with MHC class I molecules. Ligation of NK-cell receptors
leads to tyrosine phosphorylation of receptor-associated cyto-
plasmic activating (ITAM) or inhibitory (ITIM) motifs, initiating
the relevant downstream signalling pathways. A single NK cell
expresses several different activating and inhibitory receptors,
and the outcome of a NK cell–target cell interaction depends on
the balance between activating and inhibitory signalling.
In order to study the role of ligand dimensions in NK-cell acti-
vation, we have generated elongated forms of the MHC class I
homologue H60a, a mouse NKG2D ligand [9–11] and expressed
them stably in the RMA cell line. As inhibitory ligands for mouse NK
c e l l sw eh a v eu s e dt h eM H Cc l a s sIH - 2 K
b molecule, a ligand for the
Ly49C receptor, and Qa1
b, ligand for CD94/NKG2A, together with
elongated versions of these ligands. For ligand elongation we
inserted two, three or four Ig domains from human CD2, mouse
CD22 containing a mutation that makes it non-functional and
human CD4, respectively. These were the same inserts used in our
previous work on the role of ligand dimensions in T-cell activation
[2, 3], and were selected because they were likely to be inert for
mouse NK cells. Our results show that small ligand dimensions are
important for both NK-cell activation and inhibition. This ﬁnding
extends the signiﬁcance of ligand-receptor dimensions to an addi-
tional type of lymphocyte, emphasising that similar principles may
be important in controlling receptor-mediated responses during
cell–cell interactions for all lymphocytes.
Results
Engineering elongated H60a molecules
In order to investigate the importance of ligand dimensions in
NK-cell activation, we generated elongated forms of H60a,
a NKG2D ligand that is a structural homologue of the
a1a2 platform of MHC class I. Use of a NKG2D ligand offers
distinct advantages, as all mouse NK cells express NKG2D [12],
and the NKG2D signalling pathways are relatively well
understood [13]. Elongated forms of MHC class I [2, 3] and
CD48 [5] were generated previously by insertion of indepen-
dently-folding Ig domains into extracellular, membrane-proximal
regions of these molecules. We used a similar approach to create
elongated forms of H60a (Fig. 1A). A unique BamHI restriction
site was introduced in the membrane-proximal region
of the molecule (Fig. 1A), and inserts encoding two or four Ig
domains derived from CD2 or CD4 were ligated in, to create
constructs encoding H60a-CD2 and H60a-CD4 molecules,
respectively. The constructs were stably expressed in the RMA
cell line, with good cell surface expression as determined using
anti-H60 antibody staining (Fig. 1B). The correct size of
these engineered molecules was conﬁrmed by western blotting
(data not shown).
Figure 1. Elongated forms of H60a are expressed at the cell surface,
and bind NKG2D. (A) Schematic representation of H60a and its
elongated forms, created by insertion of additional Ig-like domains
from human CD2 (H60a-CD2) or human CD4 (H60a-CD4) into the
membrane-proximal region of H60a. The amino acid sequence of the
relevant portion of H60a is shown below. The sequence in blue
indicates the amino acids changed by addition of the BamHI restriction
site, and the position of the transmembrane (TM) region is indicated.
(B) Representative cell surface expression of the H60a constructs in
FACS-sorted RMA cells, stained with either anti-H60 antibody or
NKG2D tetramer. Untransfected RMA cells stained with the relevant
reagent were used as a negative control.
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Elongation of H60a by insertion of additional Ig domains may
potentially interfere with the correct folding of the a1a2 platform
of H60a, impairing NKG2D binding. To test this possibility, we
investigated NKG2D binding to the standard and elongated H60a
molecules using soluble NKG2D tetramer binding and a cellular
conjugation assay. NKG2D tetramer stained the RMA cells
expressing H60a, H60a-CD2 or H60a-CD4 strongly (Fig. 1B),
reﬂecting exactly the pattern of antibody staining, strongly
suggesting that elongation of H60a did not affect NKG2D
binding. Moreover, titration of the NKG2D tetramer showed that
the different H60a molecules had very similar afﬁnities for
soluble NKG2D (data not shown). The transfected cells shown in
Fig. 1 were used to establish NKG2D binding to the different
H60a ligands, but for subsequent use in functional experiments as
targets, sorted cells with closely matched H60a ligand levels were
used. We then probed the interaction between H60a and NKG2D
in the context of cellular interactions using a conjugation assay.
RMA cells expressing H60a, H60a-CD4 or untransfected RMA
cells were labelled with PKH67 membrane dye and co-incubated
for 10min with IL-2 expanded B6 NK cells, labelled with PKH26
membrane dye. NK cells formed few conjugates with the
untransfected RMA cells, and the conjugation increased when
RMA cells expressed the standard H60a (Fig. 2). NK cells formed
conjugates with RMA cells expressing H60a or the elongated
H60a-CD4 equally well (Fig. 2), conﬁrming that elongation of
H60a does not alter NKG2D binding.
Elongation of H60a reduces NK-cell lysis in vitro
In order to investigate the functional consequences of ligand
elongation on activation of NK cells, we used RMA cells
expressing the unaltered or elongated forms of H60a as target
cells in NK-cell chromium release cytotoxicity assays. Using IL-2
expanded NK cells as the effectors, we observed high levels of
lysis of RMA cells expressing the WT H60a molecule
(Fig. 3A). RMA cells expressing the elongated H60a molecules
were lysed signiﬁcantly less efﬁciently (Fig. 3A), with lysis levels
of targets expressing H60a-CD4 reduced to approximately half
those of targets expressing the standard H60a. In order to verify
this ﬁnding, we repeated the killing assay using ex vivo NK cells as
effectors. We observed lower levels of lysis overall, consistent
with the unstimulated phenotype of freshly isolated NK cells
(Fig. 3B). As observed with the IL-2 expanded NK cells, ex vivo NK
cells lysed RMA1H60a cells signiﬁcantly more efﬁciently than
RMA cells expressing the elongated H60a molecules (Fig. 3B).
These results demonstrated that H60a elongation reduces
NKG2D-dependent activation of NK cells. We could not deter-
mine the effect of H60a elongation on the NK-cell cytokine
response, because there was no IFN-g secretion in response to the
RMA cells expressing the standard form of H60a (data not
shown), possibly reﬂecting relatively low levels of H60a cell
surface expression.
Elongation of H60a reduces NK-cell lysis in vivo
Following the observed reduction of in vitro NK cells lysis of RMA
cells expressing similar levels of the elongated forms of H60a
molecule (Fig. 3), the physiological relevance of these ﬁndings
was tested using an in vivo killing assay. Two cell populations,
labelled separately with the membrane dyes PKH26 and PKH67,
was injected i.p. into B6 mice at 1:1 ratio (see Materials and
methods). After 48h, the intraperitoneal lavage was analysed by
ﬂow cytometry. The input cell mixtures were analysed before
injection, and an aliquot was also cultured for 48h in vitro,t o
allow detection of any differences in dye loss between the two
cell populations. When untransfected RMA cells were labelled
separately with PKH26 and PKH67 and injected at 1:1 ratio, the
original 1:1 ratio was observed 48h later in the peritoneal lavage
and after culture in vitro (Fig. 4A). This demonstrated that the
labelling with the membrane dyes had no effect on RMA cell
Figure 2. Elongated H60a supports efﬁcient cell conjugate formation
with NK cells. (A) Untransfected RMA cells (UN), or RMA cells
expressing H60a or H60a-CD4, were labelled with PKH67 membrane
dye, mixed with IL-2-expanded NK cells that had been labelled with
PKH26 membrane dye and conjugate formation was then investigated
using ﬂow cytometry, as described in the Materials and methods.N K
cells were pooled from groups of ﬁve mice. (B) Graph showing data
from three independent experiments (1, 2 and 3), using different
batches of NK cells. Experiment 1 is shown in (A).
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were injected together with RMA cells expressing H60a, there
was loss of RMA1H60a cells, relative to the untransfected RMA
cells (Fig. 4B). Although there was some apparent loss of H60a
cells relative to untransfected RMA cells in the in vitro culture,
presumably due to a reduced rate of proliferation of the
transfected cells, this was much less than the loss of H60a cells
in vivo. Therefore, H60a expression on RMA cells stimulated lysis
in vivo. When untransfected RMA cells were injected with RMA
cells expressing the elongated H60a-CD4 molecule, some reduc-
tion of the H60a-CD4/RMA ratio was observed for both the
peritoneal lavage and in vitro culture (Fig. 4C). However, the loss
of RMA cells expressing the elongated H60a-CD4 molecules after
the i.p. injection was much less than that of RMA cells expressing
the unaltered H60a molecule, strongly suggesting that elongation
of H60a reduces in vivo lysis. Differentially labelled H60a and
H60a-CD4 cells were co-injected (Fig. 4D) in order to compare
directly in vivo lysis of these two cell lines. In the peritoneal
lavage, we observed loss of RMA cells expressing the unaltered
H60a molecule relative to RMA cells expressing the H60a-CD4
molecule, even though RMA1H60a cells apparently proliferated
more rapidly than RMA1H60a-CD4 cells in vitro (Fig. 4D),
demonstrating directly that elongation of H60a reduces in vivo
lysis. The 48h lavage samples had a variable number of auto-
ﬂuorescent cells, which showed up on the diagonal of the ﬂow
cytometry plots (Fig. 4), which were probably macrophages.
However, these cells did not interfere with the in vivo killing
assay.
Elongation of H60a reduces lysis by CD45
 /  NK cells
Elongation of H60a reduced NK-cell lysis in vitro and in vivo
(Figs. 3 and 4); however the molecular mechanism of this effect is
not known. It has been proposed that the relatively small
dimensions of lymphocyte receptors and their ligands are critical
for receptor triggering, as they induce size-dependent segregation
of receptor-ligand complexes away from large phosphatases, such
as CD45, thus allowing efﬁcient phosphorylation of receptor-
associated signalling motifs and initiation of signalling [14]. CD45
plays an important role in lymphocyte receptor signalling, and
CD45 deﬁcient mice display severe impairment of T- and
B-cell development [15]. CD45 deﬁcient mice have elevated
numbers of NK cells, and these NK cells are competent in killing
but not cytokine production [16, 17]. In order to determine
whether the reduced NK-cell activation observed in response to
RMA cells expressing the elongated forms of H60a was a result of
decreased segregation away from the CD45 phosphatase, we tested
the functional consequences of ligand elongation using CD45
 / 
NK cells. If H60a elongation reduces NK-cell activation solely
because it decreases segregation of the engaged NKG2D from the
CD45 phosphatase, then H60a elongation should have no effect on
the activation of CD45
 /  NK cells. When CD45
 /  NK cells were
used as effectors in killing assays with RMA cells expressing the
standard or elongated H60a molecules as the targets, we observed
that elongation of H60a reduced lysis by these NK cells in the same
manner as for CD45 positive WT NK cells (Fig. 5), demonstrating
that the effects of ligand elongation were not solely caused by
reduced segregation of CD45 from NKG2D.
Ligand elongation reduces inhibition of NK-cell
functions
Relatively small ligand size is critical for T-cell [2, 3, 5] and NK-
cell activation, as shown here. Because NK-cell inhibitory
receptors are relatively small molecules that recognise equally
small MHC class I molecules, we investigated whether ligand
dimensions play a role in regulation of inhibition of NK-cell
functions. The outcomes of NK-cell activating and inhibitory
signalling are dramatically different, but the initiation of both
types of signalling depends on tyrosine phosphorylation of
receptor-associated signalling motifs. Therefore, it is plausible
to suggest that NK-cell activating and inhibitory receptors may
Figure 3. Elongation of H60a reduces NK cell lysis in vitro. Untrans-
fected RMA cells (UN), RMA1H60a, RMA1H60a-CD2 and RMA1H60a-
CD4 cells expressing similar levels of ligands were used as targets for
(A) IL-2-expanded NK cells or (B) ex vivo B6 NK cells in
51Cr release
assays at the indicated effector to target (E:T) ratios. Data show mean1
SD (n54). Two-tailed p values from unpaired t tests of signiﬁcant
difference are indicated for the data columns (20:1 E:T ratio). Data are
representative of ﬁve (A) and two (B) independent experiments.
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dimensions of receptor-ligand complexes. We used previously
described [2] CHO cells expressing H-2K
b molecules and their
elongated forms, because the mouse inhibitory Ly49C and Ly49I
receptors recognise H-2K
b molecules, and untransfected CHO
cells were shown to activate B6 NK cells [18]. The H-2K
b
molecules were expressed in the form of a single chain trimer
(K
bOVA SCT), consisting of the H-2K
b heavy chain, b2-micro-
globulin and the OVA peptide fused together with ﬂexible linkers.
Three elongated forms of K
bOVA SCT were used: K
bOVA SCT-
CD2, K
bOVA SCT-CD22 and K
bOVA SCT-CD4, containing an
additional two, three or four Ig domains in their membrane-
proximal region, respectively [2]. CHO cells expressing similar
levels of the standard or elongated K
bOVA SCT constructs were
used as targets in NK-cell functional assays. B6 NK cells were
sorted magnetically into Ly49C/I-enriched (approximately
75–80% Ly49C/I-positive cells) and Ly49C/I-depleted (approxi-
mately 95% Ly49C/I-negative cells) subsets, expanded in IL-2
and used as effectors. We could not compare directly inhibition
of NK-cell functions mediated by K
bOVA SCT with conventional
Figure 4. Elongation of H60a reduces lysis in vivo. The two indicated RMA cell populations were labelled separately with different membrane dyes,
and injected at a 1:1 ratio i.p. into B6 mice. After 48h, the peritoneal lavage was analysed by ﬂow cytometry. Examples of the labelled cell
populations analysed immediately before injection, after 48h culture in vitro and in the peritoneal lavage are shown. (A) Untransfected RMA (UN)
and untransfected RMA (UN). (B) RMA1H60a and untransfected RMA. (C) RMA1H60a-CD4 and untransfected RMA. (D) RMA1H60a-CD4 and RMA1
H60a. Data are representative of four (A–C) and two (D) independent experiments, using two to four mice per group for each experiment.
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b heavy chain, because expression of H-2K
b heavy chain (but
not of K
bOVA SCT) in CHO cells decreased cell surface expression
of the hamster MHC class I molecule Hm1-C4 (data not shown),
which is the major activating ligand for B6 NK cells [19].
Expression of K
bOVA SCT on CHO cells inhibited both lysis and
cytokine production by Ly49C/I-enriched, but not Ly49C/I-
depleted NK cells (Fig. 6), demonstrating that K
bOVA SCT can
be recognised by Ly49C and/or Ly49I. Elongation of K
bOVA SCT
molecules resulted in decreased inhibition of both lysis and
cytokine secretion by Ly49C/I-enriched NK cells (Fig. 6), but had
no effect on the functions of Ly49C/I-depleted NK cells,
suggesting that small ligand dimensions are important for
inhibition of NK-cell functions. To conﬁrm this ﬁnding, we
generated a Qa1
b SCT presenting the Qdm peptide, and three
elongated forms: Qa1SCT-CD2, Qa1SCT-CD22 and Qa1-CD4,
analogous to the three elongated forms of K
bOVA SCT [2]. These
constructs were expressed in CHO cells and the transfectants
were FACS-sorted to give very similar levels of cells surface
expression of the Qa1
b molecule (data not shown). NK cells were
magnetically sorted into CD94/NKG2A/C/E-enriched (greater
than 95% purity) and CD94/NKG2A/C/E-depleted (approxi-
mately 90% purity) cells and expanded in IL-2. Expression of
Qa1 SCT did not inhibit lysis by CD94/NKG2A/C/E-enriched NK
cells (data not shown), but strongly inhibited IFN-g secretion
by CD94/NKG2A/C/E-enriched, but not CD94/NKG2A/C/E-
depleted NK cells (Fig. 7). Elongated forms of Qa1 SCT did not
inhibit IFN-g secretion by CD94/NKG2A/C/E-enriched NK cells
(Fig. 7), conﬁrming that small ligand dimensions are important
for inhibition of NK-cell functions.
Discussion
Previously, we have demonstrated the importance of small ligand
dimensions for CD8
1 T-cell activation by experimental elonga-
tion of MHC class I molecules [2, 3]. In the present study, similar
elongation of ligands for the activating NKG2D and the inhibitory
Ly49C and/or Ly49I and CD94/NKG2A receptors was found to
reduce NK-cell activation and inhibition, respectively. The
observed decrease in NK-cell activation was not caused by altered
receptor binding afﬁnity for the engineered H60a molecules,
because target cells expressing the standard and elongated forms
of ligands displayed comparable levels of staining with soluble
Figure 5. Elongation of H60a reduces lysis by both CD45
 /  and wild-
type NK cells. Untransfected RMA cells (UN), RMA1H60a and RMA1
H60a-CD4 cells were used as targets for IL-2-expanded CD45
 /  or WT
NK cells in chromium release cytotoxicity assays. Data show mean1SD
(n54) and are representative of two independent experiments.
Figure 6. Elongation of the H-2K
b molecule reduces inhibition of
Ly49C/I-enriched NK cells. Untransfected CHO cells (UN), or CHO cells
expressing the standard K
bOVA SCTor its elongated forms K
bOVA SCT-
CD2, K
bOVA SCT-CD22 or K
bOVA SCT-CD4 were used as targets for IL-2-
expanded Ly49C/I-enriched and Ly49C/I-depleted NK cells in (A)
cytotoxicity (effector to target ratio 20:1) and (B) IFN-g release assays
(effector to target ratio 1:5). Data show mean1SD (n54) and are
representative of six independent experiments.
Figure 7. Elongation of the Qa1
b molecule reduces inhibition of
cytokine release. CHO cells expressing the standard Qa1 SCT or its
elongated forms Qa1 SCT-CD2, Qa1 SCT-CD22 or Qa1 SCT-CD4 were
used as targets with IL-2-expanded CD94/NKG2A/C/E-enriched and
CD94/NKG2A/C/E-depleted NK cells in IFN-g release assays, at an
effector to target ratio of 1:5. Data show mean1SD (n54) and are
representative of three independent experiments.
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with NK cells. An important issue is whether the inserted Ig
spacer domains are inert and only act as spacers, or could in
themselves be having an effect. We chose to use exactly the same
Ig domains used in our previous work on increasing the
dimensions of MHC class I molecules [2, 3]. It seems unlikely
that if the spacer domains were having functional effects they
could cause both a decrease of NK-cell activation (H60a
experiments), and an apparent increase of NK-cell activation
(H-2K
b and Qa1 experiments). We have also demonstrated
directly that single chain versions of MHC class I molecules can
be recognised by receptors on NK cells to inhibit both cytotoxicity
and cytokine production, emphasising the utility of these
constructs. Similar MHC class I SCT constructs were used
previously by others to investigate NK-cell education and function
[20, 21]. Our ﬁndings suggest that NK-cell activating and
inhibitory receptors may share a common mechanism of receptor
triggering that depends on relatively small ligand size, and are
consistent with the hypothesis that ectodomain size-dependent
protein segregation at the cell contact interface plays a role NK-
cell receptor triggering, as proposed by the kinetic-segregation
model [14].
The kinetic-segregation model of receptor triggering proposes
that during lymphocyte target cell interactions, exclusion of
proteins with large ectodomains, such as the CD45 and CD148
tyrosine phosphatases, from close-contact zones formed by
interacting receptor and ligand pairs of small dimensions, shifts
the balance of constitutive phosphorylation and dephos-
phorylation towards phosphorylation, allowing receptor trigger-
ing [14]. Some previously described features of NK-cell receptor
signalling indicate that the model may be applicable to NK cells.
Signalling via NK-cell activating and inhibitory receptors is initi-
ated by tyrosine phosphorylation of receptor-associated cyto-
plasmic sequences. Murine NKG2D associates with the DAP10
and DAP12 adaptor molecules, whereas Ly49C, Ly49I and
NKG2A contain an ITIM sequence in their cytoplasmic tails.
Treatment with pervanadate, a protein tyrosine phosphatase
inhibitor, results in DAP10 phosphorylation [22, 23] and in
Ly49C phosphorylation [24] in unstimulated NK cells. This
suggests that the NK-cell receptor signalling motifs are being
constitutively phosphorylated and dephosphorylated, even in the
absence of receptor ligation, although it is possible that perva-
nadate may also activate some tyrosine kinases. Upon ligand
binding, this phosphorylation and dephosphorylation balance
must change in favour of tyrosine phosphorylation. The phos-
phatases mediating NK-cell receptor associated motif dephos-
phorylation have not as yet been identiﬁed. However, there is
some evidence that NK-cell receptor signalling motifs are
substrates for CD45, as DAP12 is hyperphosphorylated in CD45-
deﬁcient NK cells [25]. However, elongation of H60a reduced
activation of CD45
 /  NK cells (Fig. 5), demonstrating that the
effects of ligand elongation observed here were not solely caused
by reduced segregation of CD45 from NKG2D. However, there
remains a possibility of size-dependent segregation from
other phosphatases with large ectodomains. Electron microscopy
examination of human NK cells interacting with target cells
expressing a ligand for the inhibitory receptor KIR2DL1 revealed
the presence of wide and narrow regions between the apposing
membranes, and accumulation of the ligand in the narrow
regions, as predicted by the kinetic-segregation model [26].
Moreover, phosphorylated KIR2DL1 molecules were observed to
localise in microclusters during inhibitory interactions [27].
The relatively small dimensions of NK-cell activating and
inhibitory receptor–ligand complexes may facilitate their size-
dependent co-localisation at the NK-cell immunological synapse,
thus facilitating signal integration. Co-localisation of human
inhibitory and activating NK-cell receptors was demonstrated
previously for the activating receptors CD2 and 2B4, and inhibi-
tory KIR2DL1/2 receptors [28]. It is not yet known whether
efﬁcient inhibition of NK-cell activating signalling requires co-
localisation of the activating and inhibitory receptors [29].
Phosphorylated ITIM sequences can recruit the SHP-1, SHP-2 and
SHIP phosphatases, which then dephosphorylate, directly or
indirectly, several proteins involved in the activation of NK-cell
responses. Critically, SHP-1 and SHP-2 are active only when
bound to the ITIM motifs, as this releases the phosphatase cata-
lytic domain from an inhibitory interaction with the N-terminal
SH2 domain. Therefore, NK-cell inhibition is spatially restricted
and is predicted to be efﬁcient only if the engaged activating and
inhibitory receptors are localised within relative proximity. The
reduction of inhibition of NK-cell functions observed here after
elongation of the H-2K
b or Qa1
b molecules may result from size-
dependent segregation of the small, unaltered activating
complexes from the experimentally elongated inhibitory
complexes. Further work investigating the functional conse-
quences of the simultaneous elongation of ligands for both acti-
vating and inhibitory receptors is required to test this possibility.
Our results suggest that size-dependent protein segregation at
the interface between NK cell and target cell is critical for
controlling NK-cell activation, as experimental elongation of
ligands for NKG2D or Ly49C and/or Ly49I resulted in a decrease
of NK-cell activation or inhibition, respectively. We propose that
size-dependent protein segregation is a general mechanism that
initiates and/or facilitates lymphocyte receptor triggering. Some
activating and inhibitory NK-cell receptors are also expressed on
other cell types. NKG2D can be expressed on activated CD8
1
T cells, subsets of gd T cells and NKT cells [12]. Ly49C/I can be
expressed on subsets of T cells [30], NKT cells [31] and B-1 cells
[32]. The general principle of size-dependent protein segregation
should also apply to triggering of these NK-cell receptors on other
cell types. A range of NK-cell receptors that can signal via ITAM or
ITIM-containing cytoplasmic sequences have been described;
however, ligands for some of them have not yet been identiﬁed.
Based on the work presented here, we predict that these as yet
unidentiﬁed NK-cell ligands have relatively small ectodomains. A
requirement for small ligand dimensions in effective regulation of
NK-cell function has important implications for the identiﬁcation
of natural ligands for NK-cell receptors, and similarly for the
manipulation of NK-cell receptors/ligands for possible ther-
apeutic purposes.
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Antibodies
The following mAb were used, obtained from BD Pharmingen
unless indicated otherwise: anti-H60 clone 205326 (R&D
Systems), anti-Qa1
b clone 6A8.6F10.1A6, anti-Ly49C/I clone
5E6, anti-NKG2A/C/E clone 20d5, anti-H-2K
b clone CTKb (AbD
Serotec), anti-CD49b clone DX5 and anti-NK1.1 clone PK136.
Recombinant DNA constructs
Standard molecular biology techniques were used. A unique
BamHI restriction site was introduced into the H60a sequence
cloned into the pKG4 mammalian expression vector using the
forward 50caaatgccactcagctggatccacagtgaataacttc 30 and the
reverse 50gaagttattcactgtaggatccagctgagtggcatttg 30 oligonucleo-
tides by directed mutagenesis using a QuickChange mutagenesis
kit (Stratagene), according to the manufacturer’s instructions.
Inserts encoding domains 1 and 2 of human CD2 (for H60a-CD2),
or domains 1–4 of human CD4 (for H60a-CD4), were excised
from the previously described equivalent elongated K
bOVA SCT
constructs [2], and ligated into the new BamHI site in the H60a
cDNA. A new Qa1
b SCT presenting the Qdm peptide
(AMAPRTLLL), and the three elongated forms of Qa1
b SCT were
generated exactly as described previously for the K
bOVA SCT
molecules [2], using an introduced unique BamHI restriction site.
Cell cultures and transfection
RMA cells were cultured in RPMI 1640 medium with 2mM
glutamine and 10% FBS. RMA cells were transfected by
electoporation (Amaxa Biosystems, nucleofection kit L, program
C-1). Stable RMA transfectants were selected using 1mg/mL
Geneticin (G418 sulphate). CHO cells were cultured in nutrient
mixture F-12 (Ham) with 4mM glutamine and 5% FBS. CHO cells
were transfected using poly-L-ornithine [33]. Stable CHO
transfectants were selected using 0.8mg/mL Geneticin. Trans-
fectants were FACS-sorted (FACSDiva, BD) for cell surface
expression of the relevant molecule. All media and supplements
were from Invitrogen.
NKG2D tetramer staining and cellular conjugation
assay
In total, 5 10
5 cells were stained with PE-conjugated NKG2D
tetramers [34] diluted 1:100 in PBS/1% BSA. Following 30min
incubation on ice, cells were washed and analysed by ﬂow
cytometry (CyAn
TM
, Beckman Coulter). To investigate conjugate
formation, NK and RMA cells were labelled with 4mM PKH26 and
PKH67 membrane dyes (Sigma), respectively, according to the
manufacturer’s instructions. PKH26 and PKH67 are detected on
the ﬂow cytometer channels FL2 and FL1, respectively. Following
extensive washing, the cells were rested for 1h at 371C. Labelled
NK and target cells were mixed at a 1:2 ratio and incubated at
371C. After 10min incubation, the cells were ﬁxed using Cytoﬁx
(BD), gently resuspended and analysed immediately by ﬂow
cytometry. Quadrants were set to deﬁne FL1
high, FL2
high and
FL1
high/FL2
high cell populations. The percentage of FL1
high/
FL2
high events relative to total events was taken as an estimate
of conjugate formation.
NK-cell isolation and culture
Spleens were harvested from 8–10wk-old female C57BL/6 mice
(Harlan). NK cells were isolated from splenocyte suspensions by
magnetic separation using a Mouse NK Cell Isolation kit (Miltenyi
Biotec). This allowed the isolation of untouched NK cells by positive
depletion of other cell types. When required, freshly isolated NK cells
were stained with PE-conjugated antibody for the receptor of interest
and subjected to magnetic separation into the positive and negative
populations, using anti-PE microbeads (Miltenyi Biotec). Anti-
Ly49C/I (clone 5E6) and anti-NKG2A/C/E (clone 20d5) antibodies
were used in this way. NK cells were cultured in RPMI 1640 with
2mM glutamine and 10% heat-inactivated FBS, 20mM2 - m e r c a p -
toethanol, 1mM sodium pyruvate, 1mM MEM non-essential amino
acids and 1000U/mL human recombinant IL-2 for 5 days. NK cells
from CD45
 /  mice [15] on the B6 background were isolated and
cultured using the same method. The purity of NK-cell cultures was
routinely monitored by anti-CD49b (clone DX5) and anti-NK1.1
(clone PK136) antibody staining and ﬂow cytometry.
In vitro functional assays
NK-cell cytotoxicity was measured using a standard 5-h
51Cr release
assay. The levels of spontaneous
51Cr release from target cells were
below 10% in the assays. To investigate IFN-g secretion, 5 10
4 NK
cells were incubated with target cells at a 1:5 NK:target cell ratio
for 24h. Supernatant was collected and frozen for at least 24h
prior to analysis using standard IFN-g ELISA. GraphPad software
was used to perform tests of statistical signiﬁcance.
In vivo killing assay
The two populations of RMA cells to be tested were labelled
separately with 2mM PKH26 and PKH67 membrane dyes, according
to the manufacturer’s instructions. Following extensive washing,
the labelled cells were rested for at least 1h at 371C. The cells were
then re-counted, mixed at a 1:1 ratio, and 10
6 cells in total
resuspended per 0.8mL sterile PBS. An aliquot of the cell
suspension was analysed by ﬂow cytometry immediately to verify
the 1:1 ratio of the two cell populations. The cell suspension was
injected i.p. into B6 mice with 0.4mL per mouse and two to four
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2010. 40: 2050–2059 Molecular immunology 2057mice per group. A separate aliquot of the same cell suspension was
cultured in vitro (in the absence of NK cells) for later. 48h after the
injections, the mice were culled and the peritonea washed out with
PBS. The peritoneal lavage, and the equivalent in vitro culture were
then both analysed by ﬂow cytometry. All animal experiments were
carried out in accordance with UK Home Ofﬁce requirements.
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